| Entry |
|
|---|
| Name |
Moxonidine (USAN/INN);
Cynt (TN) |
|---|
| Formula |
C9H12ClN5O
|
|---|
| Exact mass |
241.073
|
|---|
| Mol weight |
241.6775
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Cardiovascular agent
DG01738 Centrally-acting antiadrenergic
|
|---|
| Remark |
|
|---|
| Efficacy |
Antihypertensive |
|---|
| Comment |
Imidazoline (clonidine type) derivative
Treatment of congestive heart failure, Treatment of type 2 diabetes (centrally acting sympatholytic)
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C02 ANTIHYPERTENSIVES
C02A ANTIADRENERGIC AGENTS, CENTRALLY ACTING
C02AC Imidazoline receptor agonists
C02AC05 Moxonidine
D05087 Moxonidine (USAN/INN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01738 Centrally-acting antiadrenergic
D05087 Moxonidine
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adrenaline
ADRA2
D05087 Moxonidine (USAN/INN)
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 16
1 C8y C 31.5823 -16.4683
2 C8y C 31.5823 -17.8612
3 C8y C 30.3641 -15.7629
4 N1b N 32.7946 -15.7629
5 N5x N 30.3641 -18.5607
6 O2a O 32.7888 -18.5607
7 N5x N 29.1459 -16.4683
8 X Cl 30.3582 -14.3582
9 C2y C 34.0128 -16.4683
10 C8y C 29.1516 -17.8729
11 C1a C 32.7888 -19.9537
12 N1x N 35.3390 -16.0368
13 N2x N 34.0114 -17.8738
14 C1a C 27.9510 -18.5781
15 C1x C 36.1594 -17.1652
16 C1x C 35.3442 -18.2992
BOND 17
1 1 2 1
2 1 3 2
3 1 4 1
4 2 5 2
5 2 6 1
6 3 7 1
7 3 8 1
8 4 9 1
9 5 10 1
10 6 11 1
11 9 12 1
12 9 13 2
13 10 14 1
14 12 15 1
15 13 16 1
16 7 10 2
17 15 16 1
|
|---|
